*Registry of 48,612 AHF patients at 259 US hospitals.10
Community study of 1282 incident-hospitalized HF patients in the US.9
Retrospective study of 2.5 million Medicare patients with HF with a mean age of 80.7
§Population study of 3695 AHF patients in the US.5
*Survey of 585 US hospitals for risk-standardized readmission rate.3
Risk of death increases progressively and independently with each AHF or cardiovascular event11
Adapted from Lee et al, 2009.
*Cohort study in 9941 patients in acute care hospitals.11
Adapted from DeVore et al, 2014.
*Retrospective, observational study of a registry of patients with AHF from more than 300 US community and academic medical centers.13
In-hospital WHF was defined as the initiation of inotropic medicine or an IV vasodilator more than 12 hours after hospital presentation, or a transfer to the intensive care unit or the administration of advanced medical therapy after the first inpatient day.13
Adapted from Palmer et al, 2015.
*Retrospective study in 55,436 hospitalized patients with AHF.14
WRF was defined as the absolute serum creatinine (SCr) and a ≥25% increase from baseline. Persistent WRF was defined as ≥0.3 mg/dL and ≥25% increase from baseline SCr that persisted at discharge. Transient WRF was defined as ≥0.3 mg/dL and ≥25% increase from baseline SCr that did not persist at discharge.14
Mortality is the primary concern in the treatment of AHF, but there are also significant financial considerations regarding treatments and hospital admissions15
*Community survey of 1054 HF patients followed until death or last follow-up (mean 4.6 years).20
You are now leaving HeartFailure.com and moving to an external website independently operated and not managed by Novartis Pharmaceuticals Corporation.
Novartis assumes no responsibility for this site. If you do not wish to leave this site, click Cancel, or click OK to continue.